AI in Healthcare

Today's Stories

1. 1

   General AI models beat specialized medical AI tools in new study

   A Nature Medicine study found that general-purpose large language models (AI systems like ChatGPT that understand and generate text) outperform AI tools specifically designed for clinical tasks. The research suggests that broad AI training may be more effective than narrow medical specialization for healthcare applications.

   Doctors and hospitals may get better results using general AI assistants rather than expensive specialized medical software currently being marketed to them.

2. 2

   Pfizer licenses AI startup's drug discovery software to speed up medicine development

   Pharmaceutical giant Pfizer signed a licensing agreement with AI startup Chai Discovery to use their artificial intelligence software for designing new antibodies and drugs. The deal allows Pfizer to accelerate the traditionally slow process of drug discovery by using AI to predict how molecules will behave.

   New medications could reach patients faster as drug companies use AI to skip years of traditional trial-and-error lab work.

3. 3

   Healthcare AI company Abridge raises $5.3 billion to expand beyond medical notes

   Abridge, which uses AI to automatically transcribe and summarize doctor-patient conversations, secured massive funding from NVIDIA and Eli Lilly. The company plans to expand from clinical note-taking into billing, drug trials, and real-time insurance claims processing to become what it calls 'the operating system for medicine.'

   Doctor visits could become more efficient with less paperwork, and insurance claims might get processed instantly instead of taking weeks.

4. 4

   Drug discovery leaders warn US funding cuts could hurt AI medical research

   Executives from pharmaceutical AI companies including NVIDIA warned that proposed cuts to US health research funding could allow other countries to take the lead in AI-powered drug development. They argued that the combination of AI and biology will determine global competitiveness for decades.

   American patients might have to wait longer for new AI-designed treatments if other countries develop better medical AI capabilities first.

5. 5

   Japanese pharma company joins global AI research consortium for drug discovery

   Nxera Pharma joined OpenFold, a non-profit consortium that develops open-source AI tools for biology and drug discovery. The group includes technology companies like Amazon Web Services, Microsoft, and NVIDIA alongside numerous pharmaceutical companies working to share AI research.

   Collaborative AI research could lead to faster development of new medicines as companies share tools instead of each developing their own from scratch.